Trial Profile
A prospective, observational study evaluating the safety and efficacy in switch from natalizumab to fingolimod in multiple sclerosis patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Feb 2016
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- 26 Feb 2016 New trial record